MicroRNA‑146a‑5p enhances ginsenoside Rh2‑induced anti‑proliferation and the apoptosis of the human liver cancer cell line HepG2

Chen,Weiwen; Chu,Shuai; Li,Haixia; Qiu,Yurong

doi:10.3892/ol.2018.9235

MicroRNA‑146a‑5p enhances ginsenoside Rh2‑induced anti‑proliferation and the apoptosis of the human liver cancer cell line HepG2

Authors:
- Weiwen Chen
- Shuai Chu
- Haixia Li
- Yurong Qiu
View Affiliations

Affiliations: Medical Laboratories, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: July 31, 2018 https://doi.org/10.3892/ol.2018.9235
Pages: 5367-5374

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is one of the leading causes of malignancy‑associated mortality worldwide and its clinical therapy remains very challenging. Ginsenoside Rh2 (Rh2) has been reported to have antitumor effects on some types of cancer, including liver cancer. However, its regulatory mechanism has not been extensively evaluated. In the present study, Rh2 increased the expression of microRNA (miR)‑200b‑5p, miR‑224‑3p and miR‑146a‑5p, and decreased the expression of miR‑26b‑3p and miR‑29a‑5p. Of the three upregulated miRs, miR‑146a‑5p exhibited the highest fold elevation. In accordance with a previous study, Rh2 effectively inhibited the survival of liver cancer cells in vitro and in a mouse model. In addition, it was observed that Rh2 markedly promoted liver cancer apoptosis and inhibited colony formation. Cell apoptosis and the inhibition of cell survival as well as colony formation induced by Rh2 were enhanced and weakened by miR‑146a‑5p overexpression and inhibition, respectively. The results of the present study provide further evidence of the antitumor effect of Rh2 in liver cancer and also demonstrate that this effect may be mediated via the regulation of miR‑146a‑5p expression in the liver cancer cell line HepG2. The results indicated that miR‑146a‑5p may be a promising regulatory factor in Rh2‑mediated effects in liver cancer.

View Figures

View References

1	Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, Kim DK and Kim ND: Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 14:869–875. 1999.PubMed/NCBI
2	Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I and Shinomiya N: Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res. 89:733–740. 1998. View Article : Google Scholar : PubMed/NCBI
3	Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M and Guns ES: Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol. 175:1926–1931. 2006. View Article : Google Scholar : PubMed/NCBI
4	Xia T, Wang YN, Zhou CX, Wu LM, Liu Y, Zeng QH, Zhang XL, Yao JH, Wang M and Fang JP: Ginsenoside Rh2 and Rg3 inhibit cell proliferation and induce apoptosis by increasing mitochondrial reactive oxygen species in human leukemia Jurkat cells. Mol Med Rep. 15:3591–3598. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yang J, Yuan D, Xing T, Su H, Zhang S, Wen J, Bai Q and Dang D: Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. J Ginseng Res. 40:400–408. 2016. View Article : Google Scholar : PubMed/NCBI
6	Yang Z, Zhao T, Liu H and Zhang L: Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep. 6:193832016. View Article : Google Scholar : PubMed/NCBI
7	Guan N, Huo X, Zhang Z, Zhang S, Luo J and Guo W: Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13. Tumour Biol. 36:6789–6795. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li S, Gao Y, Ma W, Cheng T and Liu Y: Ginsenoside Rh2 inhibits invasiveness of glioblastoma through modulation of VEGF-A. Tumour Biol. 2015.(Epub ahead of print).
9	Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T and Liu Y: EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 35:5593–5598. 2014. View Article : Google Scholar : PubMed/NCBI
10	Huang J, Peng K, Wang L, Wen B, Zhou L, Luo T, Su M, Li J and Luo Z: Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-α signaling pathway. Acta Biochim Biophys Sin (Shanghai). 48:750–755. 2016. View Article : Google Scholar : PubMed/NCBI
11	Han S, Jeong AJ, Yang H, Kang Bin K, Lee H, Yi EH, Kim BH, Cho CH, Chung JW, Sung SH and Ye SK: Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. J Ethnopharmacol. 194:83–90. 2016. View Article : Google Scholar : PubMed/NCBI
12	Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development. 132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
13	Joshi P, Middleton J, Jeon YJ and Garofalo M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wen X, Zhang HD, Zhao L, Yao YF, Zhao JH and Tang JH: Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer. Asian Pac J Cancer Prev. 16:1105–1109. 2015. View Article : Google Scholar : PubMed/NCBI
15	An IS, An S, Kwon KJ, Kim YJ and Bae S: Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells. Oncol Rep. 29:523–528. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wu N, Wu GC, Hu R, Li M and Feng H: Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin. 32:345–353. 2011. View Article : Google Scholar : PubMed/NCBI
17	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
18	Guo H and Xia B: Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer. BMC Cancer. 16:5652016. View Article : Google Scholar : PubMed/NCBI
19	Lv Q, Rong N, Liu LJ, Xu XL, Liu JT, Jin FX and Wang CM: Antitumoral activity of (20R)- and (20S)-Ginsenoside Rh2 on transplanted hepatocellular carcinoma in mice. Planta Med. 82:705–711. 2016. View Article : Google Scholar : PubMed/NCBI
20	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
21	Qiu GH, Xie X, Xu F, Shi X, Wang Y and Deng L: Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology. 67:1–12. 2015. View Article : Google Scholar : PubMed/NCBI
22	Moi P, Chan K, Asunis I, Cao A and Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar : PubMed/NCBI
23	Milkovic L, Zarkovic N and Saso L: Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 12:727–732. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zu Y, Yang Y, Zhu J, Bo X, Hou S, Zhang B, Qiu J and Zheng J: MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6. Am J Cancer Res. 6:2502–2513. 2016.PubMed/NCBI